(1'R,2'S,4'R,5'S)-phosphoric acid di-tert-butyl ester 1-(di-tert-butoxy-phosphoryloxymethyl)-4-hydroxybicyclo[3.1.0]hex-2-yl ester | 630103-41-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磷酸及其衍生物
• 英文名称: (1'R,2'S,4'R,5'S)-phosphoric acid di-tert-butyl ester 1-(di-tert-butoxy-phosphoryloxymethyl)-4-hydroxybicyclo[3.1.0]hex-2-yl ester
• 英文别名: (1'R,2'S,4'R,5'S)-phosphoric acid di-tert-butyl ester 1-(di-tert-butoxyphosphoryloxymethyl)-4-hydroxy-bicyclo[3.1.0]hex-2-yl ester；(1'R,2'S,4'R,5'S)-phosphoric acid di-tert-butyl ester 1-(di-tert-butoxyphosphoryloxymethyl)-4-hydroxybicyclo[3.1.0]hex-2-yl ester
• CAS: 630103-41-2
• 化学式: C₂₃H₄₆O₉P₂
• 分子量: 528.56
• InChiKey: FEBGIBPPZCKNOL-ZHSNQQFMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.64
• 重原子数：
  34.0
• 可旋转键数：
  9.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  109.75
• 氢给体数：
  1.0
• 氢受体数：
  9.0

反应信息

• 作为反应物：
  描述：

  (1'R,2'S,4'R,5'S)-phosphoric acid di-tert-butyl ester 1-(di-tert-butoxy-phosphoryloxymethyl)-4-hydroxybicyclo[3.1.0]hex-2-yl ester 在 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 为溶剂， 反应 75.0h， 生成 (1'R,2'S,4'S,5'S)-phosphoric acid di-tert-butyl ester 1-(di-tert-butoxyphosphoryloxymethyl)-4-(2-iodo-6-methylaminopurin-9-yl)bicyclo[3.1.0]hex-2-yl ester
  参考文献：
  名称：

  2-Substitution of Adenine Nucleotide Analogues Containing a Bicyclo[3.1.0]hexane Ring System Locked in a Northern Conformation:  Enhanced Potency as P2Y₁ Receptor Antagonists

  摘要：

  Preference for the northern (N) ring conformation of the ribose moiety of adenine nucleotide 3',5'-bisphosphate antagonists of P2Y(1), receptors was established by using a ring-constrained methanocarba (a bicyclo[3.1.0]hexane) ring as a ribose substitute (Nandanan et al. J. Med. Chem. 2000, 43, 829-842). We have now combined the ring-constrained (N)-methanocarba modification with other functionalities at the 2-position of the adenine moiety. A new synthetic route to this series of bisphosphate derivatives was introduced, consisting of phosphorylation of the pseudoribose moiety prior to coupling with the adenine base. The activity of the newly synthesized analogues was determined by measuring antagonism of 2-methylthio-ADP-stimulated phospholipase C (PLC) activity in 1321N1 human astrocytoma cells expressing the recombinant human P2Y(1), receptor and by using the radiolabeled antagonist [H-3](2)-chloro-N-6-methyl-(N)-methanocarba-2'-deoxyadenosine 3',5'-bisphosphate 5 in a newly developed binding assay in Sf9 cell membranes. Within the series of 2-halo analogues, the most potent molecule at the hP2Y(1) receptor was an (N)-methanocarba N-6-methyl-2-iodo analogue 12, which displayed a K-i value in competition for binding of [H-3]5 of 0.79 nM and a K-B value of 1.74 nM for inhibition of PLC. Thus, 12 is the most potent antagonist selective for the P2Y(1), receptor yet reported. The 2-iodo group was substituted with trimethyltin, thus providing a parallel synthetic route for the introduction of an iodo group in this high-affinity antagonist. The (N)-methanocarba-2-methylthio, 2-methylseleno, 2-hexyl, 2-(1-hexenyl), and 2-(l-hexynyl) analogues bound less well, exhibiting micromolar affinity at P2Y(1), receptors. An enzymatic method of synthesis of the 3',5'-bisphosphate from the corresponding 3'-monophosphate, suitable for the preparation of a radiophosphorylated analogue, was explored.

  DOI：

  10.1021/jm030127+
• 作为产物：
  描述：

  (1R,2S,4R,5S)-[2-acetoxy-4-(2,2-dimethyl-1,1-diphenyl-1-silapropoxy)bicyclo[3.1.0]hex-1-yl]methyl acetate 在 四氮唑 、 四丁基氟化铵 、 potassium carbonate 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 99.0h， 生成 (1'R,2'S,4'R,5'S)-phosphoric acid di-tert-butyl ester 1-(di-tert-butoxy-phosphoryloxymethyl)-4-hydroxybicyclo[3.1.0]hex-2-yl ester
  参考文献：
  名称：

  Antiaggregatory activity in human platelets of potent antagonists of the P2Y1 receptor

  摘要：

  Activation of the P2Y(1) nucleotide receptor in platelets by ADP causes changes in shape and aggregation, mediated by activation of phospholipase C (PLC). Recently, MRS2500 (2-iodo-N-6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate) was introduced as a highly potent and selective antagonist for this receptor. We have studied the actions of MRS2500 in human platelets and compared these effects with the effects of two acyclic nucleotide analogues, a bisphosphate MRS2298 and a bisphosphonate derivative MRS2496, which act as P2Y(1) receptor antagonists, although less potently than MRS2500. Improved synthetic methods for MRS2500 and MRS2496 were devised. The bisphosphonate is predicted to be more stable in general in biological systems than phosphate antagonists due to the non-hydrolyzable C-P bond. MRS2500 inhibited the ADP-induced aggregation of human platelets with an IC50 value of 0.95 nM. MRS2298 and MRS2496 also both inhibited the ADP-induced aggregation of human platelets with IC50 values of 62.8 nM and 1.5 muM, respectively. A similar order of potency was observed for the three antagonists in binding to the recombinant human P2Y(1) receptor and in inhibition of ADP-induced shape change and ADP-induced rise in intracellular Ca2+. No substantial antagonism of the pathway linked to the inhibition of cyclic AMP was observed for the nucleotide derivatives, indicating no interaction of these three P2Y(1) receptor antagonists with the proaggregatory P2Y(12) receptor, which is also activated by ADP. Thus, all three of the bisphosphate derivatives are highly selective antagonists of the platelet P2Y(1) receptor, and MRS2500 is the most potent such antagonist yet reported. (C) 2004 Elsevier Inc. All rights reserved.

  DOI：

  10.1016/j.bcp.2004.06.026

文献信息

• P2Y₁ Antagonists:  Combining Receptor-Based Modeling and QSAR for a Quantitative Prediction of the Biological Activity Based on Consensus Scoring
  作者：Stefano Costanzi、Irina G. Tikhonova、Michihiro Ohno、Eun Joo Roh、Bhalchandra V. Joshi、Anny-Odile Colson、Dayle Houston、Savitri Maddileti、T. Kendall Harden、Kenneth A. Jacobson

  DOI：10.1021/jm0700971

  日期：2007.7.1

  P2Y(1) is an ADP-activated G protein-coupled receptor (GPCR). Its antagonists impede platelet aggregation in vivo and are potential antithrombotic agents. Combining ligand and structure-based modeling we generated a consensus model (LIST-CM) correlating antagonist structures with their potencies. We docked 45 antagonists into our rhodopsin-based human P2Y(1) homology model and calculated docking scores and free binding energies with the Linear Interaction Energy (LIE) method in continuum-solvent. The resulting alignment was also used to build QSAR based on CoMFA, CoMSIA, and molecular descriptors. To benefit from the strength of each technique and compensate for their limitations, we generated our LIST-CM with a PLS regression based on the predictions of each methodology. A test set featuring untested substituents was synthesized and assayed in inhibition of 2-MeSADP-stimulated PLC activity and in radioligand binding. LIST-CM outperformed internal and external predictivity of any individual model to predict accurately the potency of 75% of the test set.